Tucatinib hemiethanolate

• CAT Number: I045068
• CAS Number: 1429755-56-5
• Molecular Formula: C26H24N8O2.1/2C2H6O
• Molecular Weight: 503.57
• Purity: ≥95%
• IUPAC Name: 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine;ethanol
• InChI: InChI=1S/2C26H24N8O2.C2H6O/c2*1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25;1-2-3/h2*4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31);3H,2H2,1H3
• InChIKey: UGAFQGGOUGJBMF-UHFFFAOYSA-N
• SMILES: CCO.CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5.CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5

Tucatinib hemiethanolate（Cat No.:I045068）is a salt form of tucatinib, a potent and selective oral tyrosine kinase inhibitor targeting HER2 (human epidermal growth factor receptor 2). It blocks HER2-driven signaling pathways, inhibiting tumor cell proliferation in HER2-positive cancers, particularly metastatic breast cancer. Tucatinib offers improved selectivity, minimizing off-target effects on EGFR and reducing associated toxicities. The hemiethanolate form enhances solubility and stability for pharmaceutical formulation. Often used in combination therapies (e.g., with trastuzumab and capecitabine), tucatinib has shown significant clinical benefit in patients with advanced or brain-metastatic HER2-positive breast cancer.